Current Issue - May 2009, Volume 3, Issue No. 1

In this study we seek to evaluate the value of tetrachlorodecaoxygen as an intra and postoperative adjuvant in the surgical management of primarily closed tibial fractures fixed with plate and screws. We reasoned that its prophagocytic and antiinflammation properties should decrease acute inflammation and associated complications. Of 41 cases of tibial fractures included in the study, seven were grade III open fractures. No adverse effects were observed from the use of tetrachlorodecaoxygen. There was no occurrence of acute compartment syndromes or chronic deep tissue infections. All subjects were able to bear weight within 16 to 24 weeks. We concluded that the use of tetrachlorodecaoxygen is of benefit when used as an adjuvant in the primary fixation and wound closure of tibial fractures.

Abstract   |   Reference